NO301369B1 - 1-aminoetylindolderivater - Google Patents
1-aminoetylindolderivater Download PDFInfo
- Publication number
- NO301369B1 NO301369B1 NO943999A NO943999A NO301369B1 NO 301369 B1 NO301369 B1 NO 301369B1 NO 943999 A NO943999 A NO 943999A NO 943999 A NO943999 A NO 943999A NO 301369 B1 NO301369 B1 NO 301369B1
- Authority
- NO
- Norway
- Prior art keywords
- mmol
- solution
- stirred
- ether
- chloro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 73
- 239000001257 hydrogen Substances 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 40
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 36
- 239000002253 acid Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 5
- 229940126601 medicinal product Drugs 0.000 claims description 5
- XJJZQXUGLLXTHO-ZETCQYMHSA-N (2S)-1-(6-chloro-5-fluoroindol-1-yl)-propan-2-amine Chemical compound FC1=C(Cl)C=C2N(C[C@@H](N)C)C=CC2=C1 XJJZQXUGLLXTHO-ZETCQYMHSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- 208000020925 Bipolar disease Diseases 0.000 claims description 3
- 208000032841 Bulimia Diseases 0.000 claims description 3
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 208000026139 Memory disease Diseases 0.000 claims description 3
- 208000019695 Migraine disease Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 206010033664 Panic attack Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 206010041250 Social phobia Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 230000003542 behavioural effect Effects 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 231100000869 headache Toxicity 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 208000019906 panic disease Diseases 0.000 claims description 3
- 208000022821 personality disease Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 3
- 208000015891 sexual disease Diseases 0.000 claims description 3
- 208000019116 sleep disease Diseases 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- BJHBBPWFHWHWOG-SSDOTTSWSA-N (2r)-1-(4-chloro-5-fluoroindol-1-yl)propan-2-amine Chemical compound FC1=CC=C2N(C[C@H](N)C)C=CC2=C1Cl BJHBBPWFHWHWOG-SSDOTTSWSA-N 0.000 claims description 2
- MYZDBEVPJGKIQS-SSDOTTSWSA-N (2r)-1-(5,6-difluoroindol-1-yl)propan-2-amine Chemical compound FC1=C(F)C=C2N(C[C@H](N)C)C=CC2=C1 MYZDBEVPJGKIQS-SSDOTTSWSA-N 0.000 claims description 2
- DUUXOYARAAZWLV-MRVPVSSYSA-N (2r)-1-(5-fluoroindol-1-yl)propan-2-amine Chemical compound FC1=CC=C2N(C[C@H](N)C)C=CC2=C1 DUUXOYARAAZWLV-MRVPVSSYSA-N 0.000 claims description 2
- XJJZQXUGLLXTHO-SSDOTTSWSA-N (2r)-1-(6-chloro-5-fluoroindol-1-yl)propan-2-amine Chemical compound FC1=C(Cl)C=C2N(C[C@H](N)C)C=CC2=C1 XJJZQXUGLLXTHO-SSDOTTSWSA-N 0.000 claims description 2
- BJHBBPWFHWHWOG-ZETCQYMHSA-N (2s)-1-(4-chloro-5-fluoroindol-1-yl)propan-2-amine Chemical compound FC1=CC=C2N(C[C@@H](N)C)C=CC2=C1Cl BJHBBPWFHWHWOG-ZETCQYMHSA-N 0.000 claims description 2
- YQZSYPKWHRXTCN-ZETCQYMHSA-N (2s)-1-[5-fluoro-4-(trifluoromethyl)indol-1-yl]propan-2-amine Chemical compound FC1=CC=C2N(C[C@@H](N)C)C=CC2=C1C(F)(F)F YQZSYPKWHRXTCN-ZETCQYMHSA-N 0.000 claims description 2
- VGCXBJQGAKERIM-ZETCQYMHSA-N (2s)-1-[5-fluoro-6-(trifluoromethyl)indol-1-yl]propan-2-amine Chemical compound FC1=C(C(F)(F)F)C=C2N(C[C@@H](N)C)C=CC2=C1 VGCXBJQGAKERIM-ZETCQYMHSA-N 0.000 claims description 2
- YMEHSPLPRQDLLW-UHFFFAOYSA-N 1-(4-methylindol-1-yl)propan-2-amine Chemical compound C1=CC=C2N(CC(N)C)C=CC2=C1C YMEHSPLPRQDLLW-UHFFFAOYSA-N 0.000 claims description 2
- UOWVUNAMIYCETC-UHFFFAOYSA-N 1-(5-bromoindol-1-yl)propan-2-amine Chemical compound BrC1=CC=C2N(CC(N)C)C=CC2=C1 UOWVUNAMIYCETC-UHFFFAOYSA-N 0.000 claims description 2
- XXCLNSYNUQMDML-UHFFFAOYSA-N 1-(5-chloroindol-1-yl)propan-2-amine Chemical compound ClC1=CC=C2N(CC(N)C)C=CC2=C1 XXCLNSYNUQMDML-UHFFFAOYSA-N 0.000 claims description 2
- DUUXOYARAAZWLV-UHFFFAOYSA-N 1-(5-fluoroindol-1-yl)propan-2-amine Chemical compound FC1=CC=C2N(CC(N)C)C=CC2=C1 DUUXOYARAAZWLV-UHFFFAOYSA-N 0.000 claims description 2
- XJJZQXUGLLXTHO-UHFFFAOYSA-N 1-(6-chloro-5-fluoroindol-1-yl)-propan-2-amine Chemical compound FC1=C(Cl)C=C2N(CC(N)C)C=CC2=C1 XJJZQXUGLLXTHO-UHFFFAOYSA-N 0.000 claims description 2
- WZMZEXSQEAPONX-UHFFFAOYSA-N 1-(6-fluoroindol-1-yl)propan-2-amine Chemical compound C1=C(F)C=C2N(CC(N)C)C=CC2=C1 WZMZEXSQEAPONX-UHFFFAOYSA-N 0.000 claims description 2
- MTKMOBVGAFBBKJ-UHFFFAOYSA-N 2-(4-chloro-5-fluoroindol-1-yl)ethanamine Chemical compound FC1=CC=C2N(CCN)C=CC2=C1Cl MTKMOBVGAFBBKJ-UHFFFAOYSA-N 0.000 claims description 2
- HBDGGXQOJCCOCL-UHFFFAOYSA-N 2-(5-fluoro-3-methoxyindol-1-yl)ethanamine Chemical compound C1=C(F)C=C2C(OC)=CN(CCN)C2=C1 HBDGGXQOJCCOCL-UHFFFAOYSA-N 0.000 claims description 2
- UEPNGPGBALZHNM-UHFFFAOYSA-N 2-(5-fluoroindol-1-yl)ethanamine Chemical compound FC1=CC=C2N(CCN)C=CC2=C1 UEPNGPGBALZHNM-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- MYZDBEVPJGKIQS-ZETCQYMHSA-N (2s)-1-(5,6-difluoroindol-1-yl)propan-2-amine Chemical compound FC1=C(F)C=C2N(C[C@@H](N)C)C=CC2=C1 MYZDBEVPJGKIQS-ZETCQYMHSA-N 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 398
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 312
- 239000000243 solution Substances 0.000 description 276
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 135
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 133
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 123
- 239000002904 solvent Substances 0.000 description 122
- 229910052938 sodium sulfate Inorganic materials 0.000 description 120
- 235000011152 sodium sulphate Nutrition 0.000 description 120
- 239000012074 organic phase Substances 0.000 description 118
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 117
- 239000013078 crystal Substances 0.000 description 109
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 106
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 95
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 93
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 81
- 239000011541 reaction mixture Substances 0.000 description 81
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 75
- 239000000741 silica gel Substances 0.000 description 75
- 229910002027 silica gel Inorganic materials 0.000 description 75
- 239000008346 aqueous phase Substances 0.000 description 73
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 68
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 66
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 64
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 62
- 239000000725 suspension Substances 0.000 description 58
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
- 239000003921 oil Substances 0.000 description 42
- 235000019198 oils Nutrition 0.000 description 42
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 42
- 239000001530 fumaric acid Substances 0.000 description 39
- 239000002585 base Substances 0.000 description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- 239000003054 catalyst Substances 0.000 description 34
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 32
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 32
- 239000012312 sodium hydride Substances 0.000 description 32
- 229910000104 sodium hydride Inorganic materials 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 32
- 239000006185 dispersion Substances 0.000 description 31
- 229910000029 sodium carbonate Inorganic materials 0.000 description 31
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 30
- 238000000354 decomposition reaction Methods 0.000 description 29
- 239000000203 mixture Substances 0.000 description 28
- 235000011121 sodium hydroxide Nutrition 0.000 description 22
- 239000012298 atmosphere Substances 0.000 description 21
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 20
- 229910003446 platinum oxide Inorganic materials 0.000 description 20
- 235000002639 sodium chloride Nutrition 0.000 description 20
- 238000001816 cooling Methods 0.000 description 18
- RBBOWEDMXHTEPA-UHFFFAOYSA-N hexane;toluene Chemical compound CCCCCC.CC1=CC=CC=C1 RBBOWEDMXHTEPA-UHFFFAOYSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- GOOHAUXETOMSMM-GSVOUGTGSA-N R-propylene oxide Chemical compound C[C@@H]1CO1 GOOHAUXETOMSMM-GSVOUGTGSA-N 0.000 description 14
- -1 methoxy, ethoxy, propoxy, isopropoxy Chemical group 0.000 description 14
- 239000012230 colorless oil Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 11
- 229910021529 ammonia Inorganic materials 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 10
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 239000012954 diazonium Substances 0.000 description 8
- 150000001989 diazonium salts Chemical class 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 150000002475 indoles Chemical class 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
- GOOHAUXETOMSMM-VKHMYHEASA-N S-propylene oxide Chemical compound C[C@H]1CO1 GOOHAUXETOMSMM-VKHMYHEASA-N 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- TUYZSKJQXNCPLN-UHFFFAOYSA-N 4-chloro-5-fluoro-1h-indole Chemical compound FC1=CC=C2NC=CC2=C1Cl TUYZSKJQXNCPLN-UHFFFAOYSA-N 0.000 description 4
- ANGRSSWNBDJESO-UHFFFAOYSA-N 6-chloro-5-fluoro-1h-indole Chemical compound C1=C(Cl)C(F)=CC2=C1NC=C2 ANGRSSWNBDJESO-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- CEPHEXXZGQBXGT-XZTIXWOLSA-N (e)-but-2-enedioic acid;(2s)-1-(6-chloro-5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=C(Cl)C=C2N(C[C@@H](N)C)C=CC2=C1 CEPHEXXZGQBXGT-XZTIXWOLSA-N 0.000 description 3
- FKKWFQULHCAHAQ-UHFFFAOYSA-N 3-methoxy-4-methyl-1h-indole-2-carboxylic acid Chemical compound C1=CC(C)=C2C(OC)=C(C(O)=O)NC2=C1 FKKWFQULHCAHAQ-UHFFFAOYSA-N 0.000 description 3
- YCVSNMPGFSFANR-UHFFFAOYSA-N 5,6-difluoro-1h-indole Chemical compound C1=C(F)C(F)=CC2=C1NC=C2 YCVSNMPGFSFANR-UHFFFAOYSA-N 0.000 description 3
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 3
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 3
- ONYNOPPOVKYGRS-UHFFFAOYSA-N 6-methyl-1h-indole Chemical compound CC1=CC=C2C=CNC2=C1 ONYNOPPOVKYGRS-UHFFFAOYSA-N 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000004992 fission Effects 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 230000018052 penile erection Effects 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- FLUDLQYYIYREOO-UHFFFAOYSA-N (1-acetyl-2-chloro-5-fluoroindol-3-yl) acetate Chemical compound C1=C(F)C=C2C(OC(=O)C)=C(Cl)N(C(C)=O)C2=C1 FLUDLQYYIYREOO-UHFFFAOYSA-N 0.000 description 2
- BJWDZGSJTOVFOG-SECBINFHSA-N (2r)-1-(3-ethyl-5-fluoroindol-1-yl)propan-2-ol Chemical compound C1=C(F)C=C2C(CC)=CN(C[C@@H](C)O)C2=C1 BJWDZGSJTOVFOG-SECBINFHSA-N 0.000 description 2
- HTJADBYJFSTXCC-SNVBAGLBSA-N (2r)-1-(3-methoxy-4-methylindol-1-yl)propan-2-ol Chemical compound C1=CC(C)=C2C(OC)=CN(C[C@@H](C)O)C2=C1 HTJADBYJFSTXCC-SNVBAGLBSA-N 0.000 description 2
- BZFWKWJIXXNMDH-MRVPVSSYSA-N (2r)-1-(4-chloro-3-ethyl-5-fluoroindol-1-yl)propan-2-ol Chemical compound C1=C(F)C(Cl)=C2C(CC)=CN(C[C@@H](C)O)C2=C1 BZFWKWJIXXNMDH-MRVPVSSYSA-N 0.000 description 2
- WHWLOHCJEPLYKB-SSDOTTSWSA-N (2r)-1-(4-chloro-5-fluoroindol-1-yl)propan-2-ol Chemical compound FC1=CC=C2N(C[C@H](O)C)C=CC2=C1Cl WHWLOHCJEPLYKB-SSDOTTSWSA-N 0.000 description 2
- DOJXLJLVFWOAII-SSDOTTSWSA-N (2r)-1-(5,6-difluoroindol-1-yl)propan-2-ol Chemical compound FC1=C(F)C=C2N(C[C@H](O)C)C=CC2=C1 DOJXLJLVFWOAII-SSDOTTSWSA-N 0.000 description 2
- JAUDOTABDVJNIV-SECBINFHSA-N (2r)-1-(5-fluoro-3-methylindol-1-yl)propan-2-ol Chemical compound FC1=CC=C2N(C[C@H](O)C)C=C(C)C2=C1 JAUDOTABDVJNIV-SECBINFHSA-N 0.000 description 2
- UWHIRZHVFOBZAC-SNVBAGLBSA-N (2r)-1-(5-fluoro-6-propan-2-ylindol-1-yl)propan-2-ol Chemical compound FC1=C(C(C)C)C=C2N(C[C@H](O)C)C=CC2=C1 UWHIRZHVFOBZAC-SNVBAGLBSA-N 0.000 description 2
- LPLAKSONRCVWSV-MRVPVSSYSA-N (2r)-1-(5-fluoroindol-1-yl)propan-2-ol Chemical compound FC1=CC=C2N(C[C@H](O)C)C=CC2=C1 LPLAKSONRCVWSV-MRVPVSSYSA-N 0.000 description 2
- DNCXFGOSLARIGP-MRVPVSSYSA-N (2r)-1-(6-chloro-3-ethyl-5-fluoroindol-1-yl)propan-2-ol Chemical compound ClC1=C(F)C=C2C(CC)=CN(C[C@@H](C)O)C2=C1 DNCXFGOSLARIGP-MRVPVSSYSA-N 0.000 description 2
- GRVMFZPJMHCAAV-MRVPVSSYSA-N (2r)-1-(6-chloro-5-fluoro-3-methylindol-1-yl)propan-2-ol Chemical compound FC1=C(Cl)C=C2N(C[C@H](O)C)C=C(C)C2=C1 GRVMFZPJMHCAAV-MRVPVSSYSA-N 0.000 description 2
- FQMZVLXPTHMGCD-SSDOTTSWSA-N (2r)-1-(6-chloro-5-fluoroindol-1-yl)propan-2-ol Chemical compound FC1=C(Cl)C=C2N(C[C@H](O)C)C=CC2=C1 FQMZVLXPTHMGCD-SSDOTTSWSA-N 0.000 description 2
- DJRULYNDBGDJDD-SSDOTTSWSA-N (2r)-1-[5-fluoro-4-(trifluoromethyl)indol-1-yl]propan-2-ol Chemical compound FC1=CC=C2N(C[C@H](O)C)C=CC2=C1C(F)(F)F DJRULYNDBGDJDD-SSDOTTSWSA-N 0.000 description 2
- YZAMLCSVCQIHJU-SSDOTTSWSA-N (2r)-1-[5-fluoro-6-(trifluoromethyl)indol-1-yl]propan-2-ol Chemical compound FC1=C(C(F)(F)F)C=C2N(C[C@H](O)C)C=CC2=C1 YZAMLCSVCQIHJU-SSDOTTSWSA-N 0.000 description 2
- WHWLOHCJEPLYKB-ZETCQYMHSA-N (2s)-1-(4-chloro-5-fluoroindol-1-yl)propan-2-ol Chemical compound FC1=CC=C2N(C[C@@H](O)C)C=CC2=C1Cl WHWLOHCJEPLYKB-ZETCQYMHSA-N 0.000 description 2
- DOJXLJLVFWOAII-ZETCQYMHSA-N (2s)-1-(5,6-difluoroindol-1-yl)propan-2-ol Chemical compound FC1=C(F)C=C2N(C[C@@H](O)C)C=CC2=C1 DOJXLJLVFWOAII-ZETCQYMHSA-N 0.000 description 2
- LPLAKSONRCVWSV-QMMMGPOBSA-N (2s)-1-(5-fluoroindol-1-yl)propan-2-ol Chemical compound FC1=CC=C2N(C[C@@H](O)C)C=CC2=C1 LPLAKSONRCVWSV-QMMMGPOBSA-N 0.000 description 2
- FQMZVLXPTHMGCD-ZETCQYMHSA-N (2s)-1-(6-chloro-5-fluoroindol-1-yl)propan-2-ol Chemical compound FC1=C(Cl)C=C2N(C[C@@H](O)C)C=CC2=C1 FQMZVLXPTHMGCD-ZETCQYMHSA-N 0.000 description 2
- ZPZHVHMLCRVMIZ-QPXDRINRSA-N (e)-but-2-enedioic acid;(2r)-1-(4-chloro-5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(C[C@H](N)C)C=CC2=C1Cl ZPZHVHMLCRVMIZ-QPXDRINRSA-N 0.000 description 2
- QIOPXGNJYZWGFM-XQGNFNNSSA-N (e)-but-2-enedioic acid;(2r)-1-(5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(C[C@H](N)C)C=CC2=C1 QIOPXGNJYZWGFM-XQGNFNNSSA-N 0.000 description 2
- CEPHEXXZGQBXGT-QPXDRINRSA-N (e)-but-2-enedioic acid;(2r)-1-(6-chloro-5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=C(Cl)C=C2N(C[C@H](N)C)C=CC2=C1 CEPHEXXZGQBXGT-QPXDRINRSA-N 0.000 description 2
- ZLKNXQYPAGILKR-PBBCPHEYSA-N (e)-but-2-enedioic acid;(2s)-1-(3-methoxy-4-methylindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(C)=C2C(OC)=CN(C[C@H](C)N)C2=C1 ZLKNXQYPAGILKR-PBBCPHEYSA-N 0.000 description 2
- ZPZHVHMLCRVMIZ-XZTIXWOLSA-N (e)-but-2-enedioic acid;(2s)-1-(4-chloro-5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(C[C@@H](N)C)C=CC2=C1Cl ZPZHVHMLCRVMIZ-XZTIXWOLSA-N 0.000 description 2
- RJGVPVVPKPNWOE-XZTIXWOLSA-N (e)-but-2-enedioic acid;(2s)-1-(5,6-difluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=C(F)C=C2N(C[C@@H](N)C)C=CC2=C1 RJGVPVVPKPNWOE-XZTIXWOLSA-N 0.000 description 2
- WGFQQJBHUDHEQL-LOOJJACZSA-N (e)-but-2-enedioic acid;(2s)-1-(5-fluoro-3-methoxy-4-methylindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(C)=C2C(OC)=CN(C[C@H](C)N)C2=C1 WGFQQJBHUDHEQL-LOOJJACZSA-N 0.000 description 2
- YAUAXOUNWGIWFN-LOOJJACZSA-N (e)-but-2-enedioic acid;(2s)-1-(6-chloro-3-ethyl-5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.ClC1=C(F)C=C2C(CC)=CN(C[C@H](C)N)C2=C1 YAUAXOUNWGIWFN-LOOJJACZSA-N 0.000 description 2
- AZBPYYRNHZXUJV-LOOJJACZSA-N (e)-but-2-enedioic acid;(2s)-1-(6-chloro-5-fluoro-3-methylindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=C(Cl)C=C2N(C[C@@H](N)C)C=C(C)C2=C1 AZBPYYRNHZXUJV-LOOJJACZSA-N 0.000 description 2
- VDKFGWSNZWBXHP-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(4-methylindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.C1=CC=C2N(CC(N)C)C=CC2=C1C VDKFGWSNZWBXHP-WLHGVMLRSA-N 0.000 description 2
- TUZFHNWMUXXNGF-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(5-chloroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.ClC1=CC=C2N(CC(N)C)C=CC2=C1 TUZFHNWMUXXNGF-WLHGVMLRSA-N 0.000 description 2
- QIOPXGNJYZWGFM-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(CC(N)C)C=CC2=C1 QIOPXGNJYZWGFM-WLHGVMLRSA-N 0.000 description 2
- RUNFLLDYCCAREH-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(5-methylindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.CC1=CC=C2N(CC(N)C)C=CC2=C1 RUNFLLDYCCAREH-WLHGVMLRSA-N 0.000 description 2
- CEPHEXXZGQBXGT-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(6-chloro-5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=C(Cl)C=C2N(CC(N)C)C=CC2=C1 CEPHEXXZGQBXGT-WLHGVMLRSA-N 0.000 description 2
- JNOQNRNBYYZFAL-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(6-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C=C2N(CC(N)C)C=CC2=C1 JNOQNRNBYYZFAL-WLHGVMLRSA-N 0.000 description 2
- XTNILVRCNMSFMC-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(3-methoxy-4-methylindol-1-yl)ethanamine Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(C)=C2C(OC)=CN(CCN)C2=C1 XTNILVRCNMSFMC-WLHGVMLRSA-N 0.000 description 2
- GLYCCROEGNEYRB-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(4-chloro-5-fluoro-3-methoxyindol-1-yl)ethanamine Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(Cl)=C2C(OC)=CN(CCN)C2=C1 GLYCCROEGNEYRB-WLHGVMLRSA-N 0.000 description 2
- QKQGVKRPPWTVGH-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(4-chloro-5-fluoroindol-1-yl)ethanamine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(CCN)C=CC2=C1Cl QKQGVKRPPWTVGH-WLHGVMLRSA-N 0.000 description 2
- FVEKPKPPRDAYBT-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(5-chloroindol-1-yl)ethanamine Chemical compound OC(=O)\C=C\C(O)=O.ClC1=CC=C2N(CCN)C=CC2=C1 FVEKPKPPRDAYBT-WLHGVMLRSA-N 0.000 description 2
- CDSYWQGVZKIGOK-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(5-fluoro-3-methoxyindol-1-yl)ethanamine Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C=C2C(OC)=CN(CCN)C2=C1 CDSYWQGVZKIGOK-WLHGVMLRSA-N 0.000 description 2
- JBSZJBAAAOFSCD-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(5-fluoroindol-1-yl)ethanamine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(CCN)C=CC2=C1 JBSZJBAAAOFSCD-WLHGVMLRSA-N 0.000 description 2
- ZRXIQWVBMPFOJX-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-(6-chloro-5-fluoroindol-1-yl)ethanamine Chemical compound OC(=O)\C=C\C(O)=O.FC1=C(Cl)C=C2N(CCN)C=CC2=C1 ZRXIQWVBMPFOJX-WLHGVMLRSA-N 0.000 description 2
- BXRCLIVSHCZBQD-UHFFFAOYSA-N 1-(2-azidopropyl)-5-chloro-2-methylindole Chemical compound ClC1=CC=C2N(CC(C)N=[N+]=[N-])C(C)=CC2=C1 BXRCLIVSHCZBQD-UHFFFAOYSA-N 0.000 description 2
- AOFHUIZQTXTIIO-UHFFFAOYSA-N 1-(2-azidopropyl)-5-chloroindole Chemical compound ClC1=CC=C2N(CC(C)N=[N+]=[N-])C=CC2=C1 AOFHUIZQTXTIIO-UHFFFAOYSA-N 0.000 description 2
- SGXLWHFMXXKWST-UHFFFAOYSA-N 1-(2-azidopropyl)-5-fluoroindole Chemical compound FC1=CC=C2N(CC(C)N=[N+]=[N-])C=CC2=C1 SGXLWHFMXXKWST-UHFFFAOYSA-N 0.000 description 2
- CRWWKSCULSZJKF-UHFFFAOYSA-N 1-(2-azidopropyl)-5-methylindole Chemical compound CC1=CC=C2N(CC(C)N=[N+]=[N-])C=CC2=C1 CRWWKSCULSZJKF-UHFFFAOYSA-N 0.000 description 2
- VSBFLRCXEAXENS-UHFFFAOYSA-N 1-(2-azidopropyl)-6-chloro-5-fluoroindole Chemical compound FC1=C(Cl)C=C2N(CC(C)N=[N+]=[N-])C=CC2=C1 VSBFLRCXEAXENS-UHFFFAOYSA-N 0.000 description 2
- OJCFSRYJRIPKCG-UHFFFAOYSA-N 1-(2-azidopropyl)-6-fluoroindole Chemical compound C1=C(F)C=C2N(CC(C)N=[N+]=[N-])C=CC2=C1 OJCFSRYJRIPKCG-UHFFFAOYSA-N 0.000 description 2
- URDQTSZWIPLSGH-UHFFFAOYSA-N 1-(2-azidopropyl)-6-methylindole Chemical compound C1=C(C)C=C2N(CC(C)N=[N+]=[N-])C=CC2=C1 URDQTSZWIPLSGH-UHFFFAOYSA-N 0.000 description 2
- LKINAALJUQRFKE-UHFFFAOYSA-N 1-(2-azidopropyl)-7-chloro-6-fluoroindole Chemical compound C1=C(F)C(Cl)=C2N(CC(C)N=[N+]=[N-])C=CC2=C1 LKINAALJUQRFKE-UHFFFAOYSA-N 0.000 description 2
- RDQQOWHCIBXDAE-UHFFFAOYSA-N 1-(3-azidobutyl)-5-fluoroindole Chemical compound FC1=CC=C2N(CCC(C)N=[N+]=[N-])C=CC2=C1 RDQQOWHCIBXDAE-UHFFFAOYSA-N 0.000 description 2
- LRUYUSYBAUTHNQ-UHFFFAOYSA-N 1-(4-chloro-5-fluoro-3-methoxyindol-1-yl)ethanone Chemical compound C1=C(F)C(Cl)=C2C(OC)=CN(C(C)=O)C2=C1 LRUYUSYBAUTHNQ-UHFFFAOYSA-N 0.000 description 2
- ZLTMBEOKYULAHF-UHFFFAOYSA-N 1-(4-methylindol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)C)C=CC2=C1C ZLTMBEOKYULAHF-UHFFFAOYSA-N 0.000 description 2
- PZJPFVNECGAOGW-WLHGVMLRSA-N 1-(5-bromoindol-1-yl)propan-2-amine;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.BrC1=CC=C2N(CC(N)C)C=CC2=C1 PZJPFVNECGAOGW-WLHGVMLRSA-N 0.000 description 2
- YEWZKNJUOVXJCT-UHFFFAOYSA-N 1-(5-bromoindol-1-yl)propan-2-ol Chemical compound BrC1=CC=C2N(CC(O)C)C=CC2=C1 YEWZKNJUOVXJCT-UHFFFAOYSA-N 0.000 description 2
- IECRNNVUKPWFKJ-UHFFFAOYSA-N 1-(5-chloro-2-methylindol-1-yl)propan-2-ol Chemical compound ClC1=CC=C2N(CC(O)C)C(C)=CC2=C1 IECRNNVUKPWFKJ-UHFFFAOYSA-N 0.000 description 2
- KDKYJTARZHNPAX-UHFFFAOYSA-N 1-(5-chloroindol-1-yl)propan-2-ol Chemical compound ClC1=CC=C2N(CC(O)C)C=CC2=C1 KDKYJTARZHNPAX-UHFFFAOYSA-N 0.000 description 2
- NIORHFSLCKPKCG-UHFFFAOYSA-N 1-(5-fluoro-3-methoxyindol-1-yl)ethanone Chemical compound C1=C(F)C=C2C(OC)=CN(C(C)=O)C2=C1 NIORHFSLCKPKCG-UHFFFAOYSA-N 0.000 description 2
- BQRGLGQCYNODKU-UHFFFAOYSA-N 1-(5-fluoroindol-1-yl)butan-2-ol Chemical compound FC=1C=C2C=CN(C2=CC=1)CC(CC)O BQRGLGQCYNODKU-UHFFFAOYSA-N 0.000 description 2
- LPLAKSONRCVWSV-UHFFFAOYSA-N 1-(5-fluoroindol-1-yl)propan-2-ol Chemical compound FC1=CC=C2N(CC(O)C)C=CC2=C1 LPLAKSONRCVWSV-UHFFFAOYSA-N 0.000 description 2
- GJNZFRRBZYEHKQ-UHFFFAOYSA-N 1-(5-methylindol-1-yl)propan-2-ol Chemical compound CC1=CC=C2N(CC(O)C)C=CC2=C1 GJNZFRRBZYEHKQ-UHFFFAOYSA-N 0.000 description 2
- FQMZVLXPTHMGCD-UHFFFAOYSA-N 1-(6-chloro-5-fluoroindol-1-yl)propan-2-ol Chemical compound FC1=C(Cl)C=C2N(CC(O)C)C=CC2=C1 FQMZVLXPTHMGCD-UHFFFAOYSA-N 0.000 description 2
- PBEOBJMKUOASMA-UHFFFAOYSA-N 1-(6-fluoroindol-1-yl)propan-2-ol Chemical compound C1=C(F)C=C2N(CC(O)C)C=CC2=C1 PBEOBJMKUOASMA-UHFFFAOYSA-N 0.000 description 2
- OCAMBOYNTKSUQJ-UHFFFAOYSA-N 1-(6-methylindol-1-yl)propan-2-ol Chemical compound C1=C(C)C=C2N(CC(O)C)C=CC2=C1 OCAMBOYNTKSUQJ-UHFFFAOYSA-N 0.000 description 2
- UAKIMDOSNLUCMB-UHFFFAOYSA-N 1-(7-chloro-6-fluoroindol-1-yl)propan-2-ol Chemical compound C1=C(F)C(Cl)=C2N(CC(O)C)C=CC2=C1 UAKIMDOSNLUCMB-UHFFFAOYSA-N 0.000 description 2
- JCDOYLBWUFVVDE-VIFPVBQESA-N 1-[(2S)-2-azidopropyl]-3-ethyl-5-fluoroindole Chemical compound C1=C(F)C=C2C(CC)=CN(C[C@H](C)N=[N+]=[N-])C2=C1 JCDOYLBWUFVVDE-VIFPVBQESA-N 0.000 description 2
- HLWXXXBNPGQJPV-JTQLQIEISA-N 1-[(2S)-2-azidopropyl]-3-methoxy-4-methylindole Chemical compound C1=CC(C)=C2C(OC)=CN(C[C@H](C)N=[N+]=[N-])C2=C1 HLWXXXBNPGQJPV-JTQLQIEISA-N 0.000 description 2
- XKKGNAFWCBEEEY-QMMMGPOBSA-N 1-[(2S)-2-azidopropyl]-4-chloro-3-ethyl-5-fluoroindole Chemical compound C1=C(F)C(Cl)=C2C(CC)=CN(C[C@H](C)N=[N+]=[N-])C2=C1 XKKGNAFWCBEEEY-QMMMGPOBSA-N 0.000 description 2
- URJITAIVJVXEKX-QMMMGPOBSA-N 1-[(2S)-2-azidopropyl]-5-fluoro-3-methoxy-4-methylindole Chemical compound C1=C(F)C(C)=C2C(OC)=CN(C[C@H](C)N=[N+]=[N-])C2=C1 URJITAIVJVXEKX-QMMMGPOBSA-N 0.000 description 2
- TXOMPTMHSIZWQY-VIFPVBQESA-N 1-[(2S)-2-azidopropyl]-5-fluoro-3-methylindole Chemical compound FC1=CC=C2N(C[C@H](C)N=[N+]=[N-])C=C(C)C2=C1 TXOMPTMHSIZWQY-VIFPVBQESA-N 0.000 description 2
- KTEMVXRLEWLGEJ-ZETCQYMHSA-N 1-[(2S)-2-azidopropyl]-5-fluoro-4-(trifluoromethyl)indole Chemical compound FC1=CC=C2N(C[C@H](C)N=[N+]=[N-])C=CC2=C1C(F)(F)F KTEMVXRLEWLGEJ-ZETCQYMHSA-N 0.000 description 2
- NUZKDDITIIAOKP-JTQLQIEISA-N 1-[(2S)-2-azidopropyl]-5-fluoro-4-propan-2-ylindole Chemical compound CC(C)C1=C(F)C=CC2=C1C=CN2C[C@H](C)N=[N+]=[N-] NUZKDDITIIAOKP-JTQLQIEISA-N 0.000 description 2
- XFNHILCYHGWBFA-ZETCQYMHSA-N 1-[(2S)-2-azidopropyl]-5-fluoro-6-(trifluoromethyl)indole Chemical compound FC1=C(C(F)(F)F)C=C2N(C[C@H](C)N=[N+]=[N-])C=CC2=C1 XFNHILCYHGWBFA-ZETCQYMHSA-N 0.000 description 2
- WWSSHMFNOSHSAV-JTQLQIEISA-N 1-[(2S)-2-azidopropyl]-5-fluoro-6-propan-2-ylindole Chemical compound C1=C(F)C(C(C)C)=CC2=C1C=CN2C[C@H](C)N=[N+]=[N-] WWSSHMFNOSHSAV-JTQLQIEISA-N 0.000 description 2
- SGXLWHFMXXKWST-QMMMGPOBSA-N 1-[(2S)-2-azidopropyl]-5-fluoroindole Chemical compound FC1=CC=C2N(C[C@H](C)N=[N+]=[N-])C=CC2=C1 SGXLWHFMXXKWST-QMMMGPOBSA-N 0.000 description 2
- ONZQHLJZPSTCNP-QMMMGPOBSA-N 1-[(2S)-2-azidopropyl]-6-chloro-3-ethyl-5-fluoroindole Chemical compound ClC1=C(F)C=C2C(CC)=CN(C[C@H](C)N=[N+]=[N-])C2=C1 ONZQHLJZPSTCNP-QMMMGPOBSA-N 0.000 description 2
- JAIZBLWCKGKWES-QMMMGPOBSA-N 1-[(2S)-2-azidopropyl]-6-chloro-5-fluoro-3-methylindole Chemical compound FC1=C(Cl)C=C2N(C[C@H](C)N=[N+]=[N-])C=C(C)C2=C1 JAIZBLWCKGKWES-QMMMGPOBSA-N 0.000 description 2
- ZZQOEHNUNKMIBY-SSDOTTSWSA-N 1-[(2r)-2-azidopropyl]-4-chloro-5-fluoroindole Chemical compound FC1=CC=C2N(C[C@@H](C)N=[N+]=[N-])C=CC2=C1Cl ZZQOEHNUNKMIBY-SSDOTTSWSA-N 0.000 description 2
- GVMHQKGONLCVJH-SSDOTTSWSA-N 1-[(2r)-2-azidopropyl]-5,6-difluoroindole Chemical compound FC1=C(F)C=C2N(C[C@@H](C)N=[N+]=[N-])C=CC2=C1 GVMHQKGONLCVJH-SSDOTTSWSA-N 0.000 description 2
- SGXLWHFMXXKWST-MRVPVSSYSA-N 1-[(2r)-2-azidopropyl]-5-fluoroindole Chemical compound FC1=CC=C2N(C[C@@H](C)N=[N+]=[N-])C=CC2=C1 SGXLWHFMXXKWST-MRVPVSSYSA-N 0.000 description 2
- VSBFLRCXEAXENS-SSDOTTSWSA-N 1-[(2r)-2-azidopropyl]-6-chloro-5-fluoroindole Chemical compound FC1=C(Cl)C=C2N(C[C@@H](C)N=[N+]=[N-])C=CC2=C1 VSBFLRCXEAXENS-SSDOTTSWSA-N 0.000 description 2
- ZZQOEHNUNKMIBY-ZETCQYMHSA-N 1-[(2s)-2-azidopropyl]-4-chloro-5-fluoroindole Chemical compound FC1=CC=C2N(C[C@H](C)N=[N+]=[N-])C=CC2=C1Cl ZZQOEHNUNKMIBY-ZETCQYMHSA-N 0.000 description 2
- GVMHQKGONLCVJH-ZETCQYMHSA-N 1-[(2s)-2-azidopropyl]-5,6-difluoroindole Chemical compound FC1=C(F)C=C2N(C[C@H](C)N=[N+]=[N-])C=CC2=C1 GVMHQKGONLCVJH-ZETCQYMHSA-N 0.000 description 2
- NMOUOXWNUBMXGO-ZETCQYMHSA-N 1-[(2s)-2-azidopropyl]-5-chloro-6-fluoroindole Chemical compound ClC1=C(F)C=C2N(C[C@H](C)N=[N+]=[N-])C=CC2=C1 NMOUOXWNUBMXGO-ZETCQYMHSA-N 0.000 description 2
- VSBFLRCXEAXENS-ZETCQYMHSA-N 1-[(2s)-2-azidopropyl]-6-chloro-5-fluoroindole Chemical compound FC1=C(Cl)C=C2N(C[C@H](C)N=[N+]=[N-])C=CC2=C1 VSBFLRCXEAXENS-ZETCQYMHSA-N 0.000 description 2
- WJFYMXAMAQJISB-UHFFFAOYSA-N 1-acetyl-4-chloro-5-fluoro-2h-indol-3-one Chemical compound C1=CC(F)=C(Cl)C2=C1N(C(=O)C)CC2=O WJFYMXAMAQJISB-UHFFFAOYSA-N 0.000 description 2
- QCBJCECRIFTTGY-UHFFFAOYSA-N 1-acetyl-5-fluoro-2h-indol-3-one Chemical compound FC1=CC=C2N(C(=O)C)CC(=O)C2=C1 QCBJCECRIFTTGY-UHFFFAOYSA-N 0.000 description 2
- LTCYMNSEASALNB-UHFFFAOYSA-N 2-bromo-1-(3,4-dimethylphenyl)ethanone Chemical compound CC1=CC=C(C(=O)CBr)C=C1C LTCYMNSEASALNB-UHFFFAOYSA-N 0.000 description 2
- MQEQTBNFWHGSRJ-UHFFFAOYSA-N 3-ethyl-5-fluoro-1h-indole-2-carboxylic acid Chemical compound C1=C(F)C=C2C(CC)=C(C(O)=O)NC2=C1 MQEQTBNFWHGSRJ-UHFFFAOYSA-N 0.000 description 2
- SBBFBVRQWAVODC-UHFFFAOYSA-N 3-methoxy-4-methyl-1h-indole Chemical compound C1=CC(C)=C2C(OC)=CNC2=C1 SBBFBVRQWAVODC-UHFFFAOYSA-N 0.000 description 2
- VPXADRLFOWLPHM-UHFFFAOYSA-N 4-chloro-5-fluoro-1h-indole-2-carboxylic acid Chemical compound FC1=CC=C2NC(C(=O)O)=CC2=C1Cl VPXADRLFOWLPHM-UHFFFAOYSA-N 0.000 description 2
- BVUNGBWDRXWQDL-UHFFFAOYSA-N 4-chloro-5-fluoro-3-methoxy-1h-indole Chemical compound C1=C(F)C(Cl)=C2C(OC)=CNC2=C1 BVUNGBWDRXWQDL-UHFFFAOYSA-N 0.000 description 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 2
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 2
- MYTGFBZJLDLWQG-UHFFFAOYSA-N 5-chloro-1h-indole Chemical compound ClC1=CC=C2NC=CC2=C1 MYTGFBZJLDLWQG-UHFFFAOYSA-N 0.000 description 2
- SCRJASFKWSLXFS-UHFFFAOYSA-N 5-fluoro-3-methoxy-1h-indole Chemical compound C1=C(F)C=C2C(OC)=CNC2=C1 SCRJASFKWSLXFS-UHFFFAOYSA-N 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- YITFSUIVLOIUGX-UHFFFAOYSA-N 6-chloro-5-fluoro-1h-indole-2-carboxylic acid Chemical compound FC1=C(Cl)C=C2NC(C(=O)O)=CC2=C1 YITFSUIVLOIUGX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- RJGVPVVPKPNWOE-QPXDRINRSA-N OC(=O)\C=C\C(O)=O.c1c(F)c(F)cc2c1ccn2C[C@H](N)C Chemical compound OC(=O)\C=C\C(O)=O.c1c(F)c(F)cc2c1ccn2C[C@H](N)C RJGVPVVPKPNWOE-QPXDRINRSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 150000008050 dialkyl sulfates Chemical class 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YHDPTFUBKZJBRC-UHFFFAOYSA-N ethyl 3-ethyl-5-fluoro-1h-indole-2-carboxylate Chemical compound C1=C(F)C=C2C(CC)=C(C(=O)OCC)NC2=C1 YHDPTFUBKZJBRC-UHFFFAOYSA-N 0.000 description 2
- OZZHTGMCIDRGEH-UHFFFAOYSA-N ethyl 4-chloro-5-fluoro-1h-indole-2-carboxylate Chemical compound FC1=CC=C2NC(C(=O)OCC)=CC2=C1Cl OZZHTGMCIDRGEH-UHFFFAOYSA-N 0.000 description 2
- BSJGKIJHMRRTDI-UHFFFAOYSA-N ethyl 5-fluoro-6-(trifluoromethyl)-1h-indole-2-carboxylate Chemical compound FC1=C(C(F)(F)F)C=C2NC(C(=O)OCC)=CC2=C1 BSJGKIJHMRRTDI-UHFFFAOYSA-N 0.000 description 2
- KITAYCDBMMPIMA-UHFFFAOYSA-N ethyl 6-chloro-5-fluoro-1h-indole-2-carboxylate Chemical compound FC1=C(Cl)C=C2NC(C(=O)OCC)=CC2=C1 KITAYCDBMMPIMA-UHFFFAOYSA-N 0.000 description 2
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropyl acetate Chemical compound CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- ZMKCHSMRBSMDEX-UHFFFAOYSA-N methyl 2-azido-3-(3-chloro-4-fluorophenyl)prop-2-enoate Chemical compound COC(=O)C(N=[N+]=[N-])=CC1=CC=C(F)C(Cl)=C1 ZMKCHSMRBSMDEX-UHFFFAOYSA-N 0.000 description 2
- BSCVUXIUVIUPCJ-UHFFFAOYSA-N methyl 5-chloro-6-fluoro-1h-indole-2-carboxylate Chemical compound ClC1=C(F)C=C2NC(C(=O)OC)=CC2=C1 BSCVUXIUVIUPCJ-UHFFFAOYSA-N 0.000 description 2
- RNEYRDIYQLBSMW-UHFFFAOYSA-N methyl 7-chloro-6-fluoro-1h-indole-2-carboxylate Chemical compound C1=C(F)C(Cl)=C2NC(C(=O)OC)=CC2=C1 RNEYRDIYQLBSMW-UHFFFAOYSA-N 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 239000003444 phase transfer catalyst Substances 0.000 description 2
- 150000005331 phenylglycines Chemical class 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229940072033 potash Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- PNWQQFHNFFKMTC-UHFFFAOYSA-N (1-acetyl-5-fluoroindol-3-yl) acetate Chemical compound C1=C(F)C=C2C(OC(=O)C)=CN(C(C)=O)C2=C1 PNWQQFHNFFKMTC-UHFFFAOYSA-N 0.000 description 1
- FAFPMTNNJIPREQ-SSDOTTSWSA-N (2r)-1-(5-chloro-6-fluoroindol-1-yl)propan-2-ol Chemical compound ClC1=C(F)C=C2N(C[C@H](O)C)C=CC2=C1 FAFPMTNNJIPREQ-SSDOTTSWSA-N 0.000 description 1
- FQHYVKRFAHVQLJ-MRVPVSSYSA-N (2r)-1-(5-fluoro-3-methoxy-4-methylindol-1-yl)propan-2-ol Chemical compound C1=C(F)C(C)=C2C(OC)=CN(C[C@@H](C)O)C2=C1 FQHYVKRFAHVQLJ-MRVPVSSYSA-N 0.000 description 1
- UTLBOWVVYRPLQR-AFIAKLHKSA-N (e)-but-2-enedioic acid;(2s)-1-(2-ethyl-5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(C[C@H](C)N)C(CC)=CC2=C1 UTLBOWVVYRPLQR-AFIAKLHKSA-N 0.000 description 1
- LVUVVWDQBQYFSO-LOOJJACZSA-N (e)-but-2-enedioic acid;(2s)-1-(4-chloro-3-ethyl-5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(Cl)=C2C(CC)=CN(C[C@H](C)N)C2=C1 LVUVVWDQBQYFSO-LOOJJACZSA-N 0.000 description 1
- YUQFRNXIHIDJLG-XZTIXWOLSA-N (e)-but-2-enedioic acid;(2s)-1-(5-chloro-6-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.ClC1=C(F)C=C2N(C[C@@H](N)C)C=CC2=C1 YUQFRNXIHIDJLG-XZTIXWOLSA-N 0.000 description 1
- ASBAZKYOOLJFNJ-AFIAKLHKSA-N (e)-but-2-enedioic acid;(2s)-1-(5-fluoro-3-methylindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(C[C@@H](N)C)C=C(C)C2=C1 ASBAZKYOOLJFNJ-AFIAKLHKSA-N 0.000 description 1
- ZUARVRNOYZSHGO-PBBCPHEYSA-N (e)-but-2-enedioic acid;(2s)-1-(5-fluoro-4-propan-2-ylindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(C[C@@H](N)C)C=CC2=C1C(C)C ZUARVRNOYZSHGO-PBBCPHEYSA-N 0.000 description 1
- JFLAQTGGAUWOLP-PBBCPHEYSA-N (e)-but-2-enedioic acid;(2s)-1-(5-fluoro-6-propan-2-ylindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=C(C(C)C)C=C2N(C[C@@H](N)C)C=CC2=C1 JFLAQTGGAUWOLP-PBBCPHEYSA-N 0.000 description 1
- QIOPXGNJYZWGFM-LOOJJACZSA-N (e)-but-2-enedioic acid;(2s)-1-(5-fluoroindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(C[C@@H](N)C)C=CC2=C1 QIOPXGNJYZWGFM-LOOJJACZSA-N 0.000 description 1
- XJTUQEHRXBXKTH-XZTIXWOLSA-N (e)-but-2-enedioic acid;(2s)-1-[5-fluoro-4-(trifluoromethyl)indol-1-yl]propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=CC=C2N(C[C@@H](N)C)C=CC2=C1C(F)(F)F XJTUQEHRXBXKTH-XZTIXWOLSA-N 0.000 description 1
- KIPNMPZZXZXXCV-XZTIXWOLSA-N (e)-but-2-enedioic acid;(2s)-1-[5-fluoro-6-(trifluoromethyl)indol-1-yl]propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.FC1=C(C(F)(F)F)C=C2N(C[C@@H](N)C)C=CC2=C1 KIPNMPZZXZXXCV-XZTIXWOLSA-N 0.000 description 1
- TYMCJVAVWDDMLZ-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(5-chloro-2-methylindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.ClC1=CC=C2N(CC(N)C)C(C)=CC2=C1 TYMCJVAVWDDMLZ-WLHGVMLRSA-N 0.000 description 1
- XTJFETPJEJPFSB-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(6-methylindol-1-yl)propan-2-amine Chemical compound OC(=O)\C=C\C(O)=O.C1=C(C)C=C2N(CC(N)C)C=CC2=C1 XTJFETPJEJPFSB-WLHGVMLRSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SXOMOLNLFJRGJI-UHFFFAOYSA-N 1-(2-azidopropyl)-4-methylindole Chemical compound C1=CC=C2N(CC(C)N=[N+]=[N-])C=CC2=C1C SXOMOLNLFJRGJI-UHFFFAOYSA-N 0.000 description 1
- JHDFOCOJZKUHAC-UHFFFAOYSA-N 1-(2-azidopropyl)-5-bromoindole Chemical compound BrC1=CC=C2N(CC(C)N=[N+]=[N-])C=CC2=C1 JHDFOCOJZKUHAC-UHFFFAOYSA-N 0.000 description 1
- SXOMOLNLFJRGJI-JTQLQIEISA-N 1-[(2S)-2-azidopropyl]-4-methylindole Chemical compound C1=CC=C2N(C[C@H](C)N=[N+]=[N-])C=CC2=C1C SXOMOLNLFJRGJI-JTQLQIEISA-N 0.000 description 1
- JZEVZCLHZQYZMU-UHFFFAOYSA-N 2-(3-methoxy-4-methylindol-1-yl)ethanamine Chemical compound C1=CC(C)=C2C(OC)=CN(CCN)C2=C1 JZEVZCLHZQYZMU-UHFFFAOYSA-N 0.000 description 1
- YVJOCSNROXMPCD-UHFFFAOYSA-N 2-(4-chloro-5-fluoro-3-methoxyindol-1-yl)ethanamine Chemical compound C1=C(F)C(Cl)=C2C(OC)=CN(CCN)C2=C1 YVJOCSNROXMPCD-UHFFFAOYSA-N 0.000 description 1
- LYEMDBHRTLIDHR-UHFFFAOYSA-N 2-(5-chloroindol-1-yl)ethanamine Chemical compound ClC1=CC=C2N(CCN)C=CC2=C1 LYEMDBHRTLIDHR-UHFFFAOYSA-N 0.000 description 1
- FOEBPVIQQCLQDC-UHFFFAOYSA-N 2-(6-chloro-5-fluoroindol-1-yl)ethanamine Chemical compound FC1=C(Cl)C=C2N(CCN)C=CC2=C1 FOEBPVIQQCLQDC-UHFFFAOYSA-N 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 1
- GVORVQPNNSASDM-UHFFFAOYSA-N 3-chloro-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Cl GVORVQPNNSASDM-UHFFFAOYSA-N 0.000 description 1
- VPFXCRBXBVXTFK-UHFFFAOYSA-N 4,5-difluoro-1h-indole-2-carboxylic acid Chemical compound FC1=CC=C2NC(C(=O)O)=CC2=C1F VPFXCRBXBVXTFK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NCNDMMJUPFOVQP-UHFFFAOYSA-N 4-chloro-3-ethyl-5-fluoro-1h-indole-2-carboxylic acid Chemical compound C1=C(F)C(Cl)=C2C(CC)=C(C(O)=O)NC2=C1 NCNDMMJUPFOVQP-UHFFFAOYSA-N 0.000 description 1
- PGFQDLOMDIBAPY-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)aniline Chemical compound NC1=CC=C(F)C(C(F)(F)F)=C1 PGFQDLOMDIBAPY-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 1
- WUVWAXJXPRYUME-UHFFFAOYSA-N 5-chloro-2-methyl-1h-indole Chemical compound ClC1=CC=C2NC(C)=CC2=C1 WUVWAXJXPRYUME-UHFFFAOYSA-N 0.000 description 1
- JXFLPDYKOWHEJF-UHFFFAOYSA-N 5-chloro-6-fluoro-1h-indole Chemical compound C1=C(Cl)C(F)=CC2=C1C=CN2 JXFLPDYKOWHEJF-UHFFFAOYSA-N 0.000 description 1
- JENHWJXKKPCHHG-UHFFFAOYSA-N 5-chloro-6-fluoro-1h-indole-2-carboxylic acid Chemical compound ClC1=C(F)C=C2NC(C(=O)O)=CC2=C1 JENHWJXKKPCHHG-UHFFFAOYSA-N 0.000 description 1
- XZLXDDMFUJUHDP-UHFFFAOYSA-N 5-fluoro-3-methoxy-4-methyl-1h-indole-2-carboxylic acid Chemical compound C1=C(F)C(C)=C2C(OC)=C(C(O)=O)NC2=C1 XZLXDDMFUJUHDP-UHFFFAOYSA-N 0.000 description 1
- XNWVWEWWPNKNJX-UHFFFAOYSA-N 5-fluoro-3-methyl-1h-indole-2-carboxylic acid Chemical compound C1=C(F)C=C2C(C)=C(C(O)=O)NC2=C1 XNWVWEWWPNKNJX-UHFFFAOYSA-N 0.000 description 1
- ISUJNJUXQUKPOL-UHFFFAOYSA-N 5-fluoro-4-(trifluoromethyl)-1h-indole-2-carboxylic acid Chemical compound FC1=CC=C2NC(C(=O)O)=CC2=C1C(F)(F)F ISUJNJUXQUKPOL-UHFFFAOYSA-N 0.000 description 1
- BLNPPAXZVRGTJI-UHFFFAOYSA-N 5-fluoro-4-propan-2-yl-1h-indole Chemical compound CC(C)C1=C(F)C=CC2=C1C=CN2 BLNPPAXZVRGTJI-UHFFFAOYSA-N 0.000 description 1
- LZPDHJKFDBEKLZ-UHFFFAOYSA-N 5-fluoro-6-(trifluoromethyl)-1h-indole-2-carboxylic acid Chemical compound FC1=C(C(F)(F)F)C=C2NC(C(=O)O)=CC2=C1 LZPDHJKFDBEKLZ-UHFFFAOYSA-N 0.000 description 1
- FAHHKWKHRHJQQN-UHFFFAOYSA-N 5-fluoro-6-propan-2-yl-1h-indole Chemical compound C1=C(F)C(C(C)C)=CC2=C1C=CN2 FAHHKWKHRHJQQN-UHFFFAOYSA-N 0.000 description 1
- YPKBCLZFIYBSHK-UHFFFAOYSA-N 5-methylindole Chemical compound CC1=CC=C2NC=CC2=C1 YPKBCLZFIYBSHK-UHFFFAOYSA-N 0.000 description 1
- ZGMJCWGXCYXCNO-UHFFFAOYSA-N 6-(carboxymethylamino)-2-chloro-3-fluorobenzoic acid Chemical compound OC(=O)CNC1=CC=C(F)C(Cl)=C1C(O)=O ZGMJCWGXCYXCNO-UHFFFAOYSA-N 0.000 description 1
- QHGMCEBXUPNWLO-UHFFFAOYSA-N 6-chloro-3-ethyl-5-fluoro-1h-indole-2-carboxylic acid Chemical compound ClC1=C(F)C=C2C(CC)=C(C(O)=O)NC2=C1 QHGMCEBXUPNWLO-UHFFFAOYSA-N 0.000 description 1
- CURQWZKBAVHJPH-UHFFFAOYSA-N 6-chloro-5-fluoro-3-methyl-1h-indole Chemical compound ClC1=C(F)C=C2C(C)=CNC2=C1 CURQWZKBAVHJPH-UHFFFAOYSA-N 0.000 description 1
- YYFFEPUCAKVRJX-UHFFFAOYSA-N 6-fluoro-1h-indole Chemical compound FC1=CC=C2C=CNC2=C1 YYFFEPUCAKVRJX-UHFFFAOYSA-N 0.000 description 1
- NWWMTPOETWQYKK-UHFFFAOYSA-N 7-chloro-6-fluoro-1h-indole Chemical compound FC1=CC=C2C=CNC2=C1Cl NWWMTPOETWQYKK-UHFFFAOYSA-N 0.000 description 1
- NJFIQCOFOZNSSU-UHFFFAOYSA-N 7-chloro-6-fluoro-1h-indole-2-carboxylic acid Chemical compound C1=C(F)C(Cl)=C2NC(C(=O)O)=CC2=C1 NJFIQCOFOZNSSU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- HWNWEADNYVHQDS-FVGYRXGTSA-N C(C=CC(=O)O)(=O)O.C(C)C1=CN(C2=CC=C(C=C12)F)C[C@H](C)N Chemical compound C(C=CC(=O)O)(=O)O.C(C)C1=CN(C2=CC=C(C=C12)F)C[C@H](C)N HWNWEADNYVHQDS-FVGYRXGTSA-N 0.000 description 1
- QAWLJAUWZHXYMQ-UHFFFAOYSA-N C(C=CC(=O)O)(=O)O.CNCC Chemical compound C(C=CC(=O)O)(=O)O.CNCC QAWLJAUWZHXYMQ-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 238000006783 Fischer indole synthesis reaction Methods 0.000 description 1
- 102000017911 HTR1A Human genes 0.000 description 1
- 101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- MOQOOKGPCBQMCY-UHFFFAOYSA-N acetic acid;hexane Chemical compound CC(O)=O.CCCCCC MOQOOKGPCBQMCY-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 150000003934 aromatic aldehydes Chemical class 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- KXHPPCXNWTUNSB-UHFFFAOYSA-M benzyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1=CC=CC=C1 KXHPPCXNWTUNSB-UHFFFAOYSA-M 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- KKJPCLMOJKUILK-UHFFFAOYSA-N ethyl 3-methoxy-4-methyl-1h-indole-2-carboxylate Chemical compound C1=CC(C)=C2C(OC)=C(C(=O)OCC)NC2=C1 KKJPCLMOJKUILK-UHFFFAOYSA-N 0.000 description 1
- OVSOYWROLOCQIS-UHFFFAOYSA-N ethyl 5,6-difluoro-1h-indole-2-carboxylate Chemical compound FC1=C(F)C=C2NC(C(=O)OCC)=CC2=C1 OVSOYWROLOCQIS-UHFFFAOYSA-N 0.000 description 1
- KSJIULFYLRMPAD-UHFFFAOYSA-N ethyl 5-fluoro-4-(trifluoromethyl)-1h-indole-2-carboxylate Chemical compound FC1=CC=C2NC(C(=O)OCC)=CC2=C1C(F)(F)F KSJIULFYLRMPAD-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- HCUARRIEZVDMPT-UHFFFAOYSA-N indolyl-2-carboxylic acid Natural products C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- RXYCUKSOYJWGPE-UHFFFAOYSA-N methyl 2-azidoacetate Chemical compound COC(=O)CN=[N+]=[N-] RXYCUKSOYJWGPE-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000003408 phase transfer catalysis Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001149 thermolysis Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/36—Oxygen atoms in position 3, e.g. adrenochrome
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Organic Insulating Materials (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH320193 | 1993-10-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO943999D0 NO943999D0 (no) | 1994-10-21 |
| NO943999L NO943999L (no) | 1995-04-24 |
| NO301369B1 true NO301369B1 (no) | 1997-10-20 |
Family
ID=4250849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO943999A NO301369B1 (no) | 1993-10-22 | 1994-10-21 | 1-aminoetylindolderivater |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5494928A (it) |
| EP (1) | EP0655440A3 (it) |
| JP (1) | JP2638752B2 (it) |
| KR (1) | KR950011406A (it) |
| CN (1) | CN1061341C (it) |
| AU (1) | AU685841B2 (it) |
| BR (1) | BR9404203A (it) |
| CA (1) | CA2132883A1 (it) |
| CO (1) | CO4290356A1 (it) |
| CZ (1) | CZ260494A3 (it) |
| FI (1) | FI944969A (it) |
| HU (1) | HU218669B (it) |
| IL (1) | IL111314A (it) |
| NO (1) | NO301369B1 (it) |
| NZ (1) | NZ264713A (it) |
| PL (1) | PL179561B1 (it) |
| RU (1) | RU2136662C1 (it) |
| TW (1) | TW270114B (it) |
| ZA (1) | ZA948094B (it) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ318228A (en) * | 1995-09-01 | 1999-07-29 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
| GB9523999D0 (en) | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
| AU3255697A (en) * | 1996-06-12 | 1998-01-07 | F. Hoffmann-La Roche Ag | A process for the manufacture of 1-(amino-alkyl)-indoles |
| AU727654B2 (en) | 1997-06-13 | 2000-12-21 | Yamanouchi Pharmaceutical Co., Ltd. | Tricyclic pyrazole derivative |
| JP4569980B2 (ja) * | 1997-08-07 | 2010-10-27 | 株式会社フジモト・コーポレーション | 新規なエチルアミン誘導体 |
| US6960579B1 (en) | 1998-05-19 | 2005-11-01 | Alcon Manufacturing, Ltd. | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders |
| ES2257869T3 (es) * | 1998-08-21 | 2006-08-01 | Novartis Ag | Nueva formulacion oral para agonistas o antagonistas de 5-ht4. |
| GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
| GB9819032D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds IV |
| GB9819019D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| EP1112106B1 (en) | 1998-09-18 | 2005-11-23 | Alcon Manufacturing Ltd. | Serotonergic 5ht2 agonists for treating glaucoma |
| FR2788772B1 (fr) * | 1999-01-26 | 2001-03-02 | Adir | Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2792313A1 (fr) * | 1999-04-13 | 2000-10-20 | Synthelabo | Derives de 2-aminoethyl-indole, leur preparation et leur application en therapeutique |
| US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| GB9918962D0 (en) | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxii |
| GB9918965D0 (en) * | 1999-08-11 | 1999-10-13 | Cerebrus Ltd | Chemical compounds xxi |
| AU2622301A (en) * | 1999-11-05 | 2001-05-14 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| AU2042301A (en) * | 1999-12-03 | 2001-06-12 | Alcon Universal Limited | 1-aminoalkyl-1H-indoles for treating glaucoma |
| JP3585796B2 (ja) | 1999-12-17 | 2004-11-04 | 新光電気工業株式会社 | 多層配線基板の製造方法、及び半導体装置 |
| EP1132389A1 (en) * | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
| US7005443B1 (en) * | 2000-03-17 | 2006-02-28 | Alcon, Inc. | 5-Hydroxy indazole derivatives for treating glaucoma |
| US7012090B1 (en) | 2000-03-17 | 2006-03-14 | Alcon, Inc. | Pyranoindoles for treating glaucoma |
| US6956036B1 (en) | 2000-03-17 | 2005-10-18 | Alcon, Inc. | 6-hydroxy-indazole derivatives for treating glaucoma |
| EP1263434A1 (en) * | 2000-03-17 | 2002-12-11 | Alcon, Inc | Compounds with 5-ht 2 and 5-ht 1a agonist activity for treating glaucoma |
| US6660870B1 (en) | 2000-03-17 | 2003-12-09 | Alcon, Inc. | 2-acylaminobenzimidazole derivatives for treating glaucoma |
| US6806285B1 (en) | 2000-03-17 | 2004-10-19 | Alcon, Inc. | 5-Hydroxyl indole derivatives for treating glaucoma |
| US6903081B2 (en) * | 2000-03-31 | 2005-06-07 | Purdue Research Foundation | Phosphoramidates and methods therefor |
| TWI288745B (en) | 2000-04-05 | 2007-10-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
| WO2001083487A1 (fr) * | 2000-04-28 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de froindazole |
| AR038762A1 (es) | 2000-10-16 | 2005-01-26 | Hoffmann La Roche | Derivados de indolina, un proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion y el uso de dichos derivados para la fabricacion de un medicamento |
| AU1529402A (en) | 2000-11-20 | 2002-05-27 | Biovitrum Ab | Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
| SE0004245D0 (sv) | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
| WO2004098807A1 (en) * | 2000-11-21 | 2004-11-18 | Barsplice Products, Inc. | Method of making steel couplers for joining concrete reinforcing bars |
| GB0030710D0 (en) * | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| HUP0303316A2 (hu) | 2000-12-20 | 2004-01-28 | Bristol-Myers Squibb Pharma Company | Aril- és amino-aril-szubsztituált szerotoninreceptor agonista és antagonista ligandumok és ezeket tartalmazó gyógyszerkészítmények |
| WO2002051844A1 (en) | 2000-12-27 | 2002-07-04 | F. Hoffmann-La Roche Ag | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
| WO2002072548A2 (en) | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
| JP2004532887A (ja) * | 2001-06-01 | 2004-10-28 | アルコン，インコーポレイテッド | 新規な融合インダゾールおよびインドールおよび緑内障治療へのこれらの使用 |
| EP1392269A1 (en) * | 2001-06-01 | 2004-03-03 | Alcon, Inc. | Novel arylaminopropane analogues and their use for the treatment of glaucoma |
| DK1392292T3 (da) * | 2001-06-01 | 2006-05-29 | Alcon Inc | Pyranoindazoler og deres anvendelse til behandling af glaukom |
| EP1405852B9 (en) | 2001-06-20 | 2013-03-27 | Daiichi Sankyo Company, Limited | Diamine derivatives |
| US7365205B2 (en) | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
| US6884816B2 (en) | 2001-08-31 | 2005-04-26 | Alcon, Inc. | Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma |
| TW593302B (en) * | 2001-12-20 | 2004-06-21 | Alcon Inc | Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
| BR0311970A (pt) | 2002-06-19 | 2005-03-29 | Biovitrum Ab | Novos compostos, seu uso e preparação |
| PL375564A1 (en) * | 2002-08-30 | 2005-11-28 | Alcon, Inc. | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma |
| US20040127395A1 (en) * | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
| KR20050033662A (ko) | 2002-09-06 | 2005-04-12 | 얀센 파마슈티카 엔.브이. | 헤테로사이클릭 화합물 |
| JP2006511556A (ja) * | 2002-12-13 | 2006-04-06 | アルコン，インコーポレイテッド | 新規のベンゾピラン類似体及び緑内障の治療のためのそれらの使用 |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| GB0314967D0 (en) | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| WO2005053688A1 (en) * | 2003-11-26 | 2005-06-16 | Alcon, Inc. | Substituted furo[2,3-g] indazoles for the treatment of glaucoma |
| US7129257B1 (en) * | 2003-12-15 | 2006-10-31 | Alcon, Inc. | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma |
| WO2005058911A2 (en) * | 2003-12-15 | 2005-06-30 | Alcon, Inc. | Substituted [1,4]oxazino[2,3-g]indazoles for the treatment of glaucoma |
| US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
| EP2400300A1 (en) | 2004-08-25 | 2011-12-28 | Takeda Pharmaceutical Company Limited | Method of screening preventives/remedies for stress urinary incontinence |
| US20060073172A1 (en) * | 2004-10-01 | 2006-04-06 | Schneider L W | Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure |
| US7425572B2 (en) * | 2004-12-08 | 2008-09-16 | Alcon, Inc. | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma |
| AU2006228378A1 (en) | 2005-03-31 | 2006-10-05 | Pfizer Products Inc. | Cyclopentapyridine and tetrahydroquinoline derivatives |
| TW200744567A (en) * | 2005-09-23 | 2007-12-16 | Alcon Inc | Phenylethylamine analogs and their use for treating glaucoma |
| EP2018863B9 (en) | 2006-05-16 | 2015-02-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| US20070293475A1 (en) * | 2006-06-20 | 2007-12-20 | Alcon Manufacturing Ltd. | Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
| CA2657640A1 (en) * | 2006-07-14 | 2008-01-24 | Pfizer Products Inc. | Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine |
| EP2216023A4 (en) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF |
| DE102008009609A1 (de) | 2008-02-18 | 2009-08-20 | Freie Universität Berlin | Substituierte 4-(Indol-3-yl)chinazoline und deren Verwendung und Herstellung |
| KR101062376B1 (ko) | 2008-04-10 | 2011-09-06 | 한국화학연구원 | 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물 |
| WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
| WO2012030953A1 (en) | 2010-09-01 | 2012-03-08 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| CN102702066A (zh) * | 2011-03-28 | 2012-10-03 | 苏州百灵威超精细材料有限公司 | 一种用于合成抗癌和减肥药物中间体6-氯-5-氟吲哚的制备新方法 |
| WO2014153203A2 (en) | 2013-03-14 | 2014-09-25 | Ossifi Inc. | Alkyl-amine harmine derivatives for promoting bone growth |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| WO2020037001A1 (en) | 2018-08-14 | 2020-02-20 | Osteoqc Inc. | FLUORO β-CARBOLINE COMPOUNDS |
| JP2022504011A (ja) | 2018-08-14 | 2022-01-13 | オステオーク インコーポレイティド | ピロロ－ジピリジン化合物 |
| JP2022523774A (ja) | 2019-02-27 | 2022-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物 |
| BR112021016620A2 (pt) | 2019-02-27 | 2021-11-03 | Univ California | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791899A (fr) * | 1971-11-26 | 1973-05-24 | Ciba Geigy | Procede de preparation d'indoles n-substitues |
| US3904617A (en) * | 1972-10-12 | 1975-09-09 | Ayerst Mckenna & Harrison | Process for preparing new heterocyclic derivatives |
| IE37234B1 (en) * | 1972-02-14 | 1977-06-08 | Ayerst Mckenna & Harrison | Fused-ring indole derivatives |
| DE2430682A1 (de) * | 1974-06-26 | 1976-01-15 | Bayer Ag | Indolyl-mono-azofarbstoffe |
| FR2355006A1 (fr) * | 1976-06-17 | 1978-01-13 | Labaz | Nouveaux derives d'indole et procedes pour les preparer |
| DE2824447A1 (de) * | 1978-06-03 | 1979-12-13 | Cassella Ag | Pyrazino-carbazole, verfahren zu ihrer herstellung und sie enthaltendes pharmazeutisches mittel |
| DE3022648A1 (de) * | 1979-06-29 | 1981-01-15 | Sandoz Ag | Neue organische verbindungen, ihre herstellung und pharmazeutischen praeparate, welche diese verbindungen enthalten |
| FR2564465B1 (fr) * | 1984-05-16 | 1986-10-03 | Cortial | Nouveaux diamino-1,3 propanols-2, leurs methodes de preparation et leurs applications therapeutiques |
| PH23498A (en) * | 1984-08-06 | 1989-08-16 | Sterling Drug Inc | 3-carbonyl-1-aminoalkyl-1h-indoles,composition and use thereof |
| US4660060A (en) * | 1985-06-17 | 1987-04-21 | The Hilton-Davis Chemical Co. | Imaging systems containing 3-(indol-3-yl)-3-(4-substituted aminophenyl)phthalides |
| NZ227850A (en) * | 1988-02-10 | 1991-11-26 | Hoffmann La Roche | Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders |
| FR2679561A1 (fr) * | 1991-07-26 | 1993-01-29 | Schneider Marc | Nouveaux derives de l'(indolyl-1) alkylamine substituee par une chaine presentant des groupements carbonyles conjugues a un noyau aromatique. |
| US5252732A (en) * | 1991-09-09 | 1993-10-12 | Merck & Co., Inc. | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity |
| EP0572863A1 (de) * | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| US5310901A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives |
-
1994
- 1994-09-07 TW TW083108265A patent/TW270114B/zh active
- 1994-09-21 CA CA002132883A patent/CA2132883A1/en not_active Abandoned
- 1994-10-03 US US08/317,259 patent/US5494928A/en not_active Expired - Fee Related
- 1994-10-07 EP EP94115800A patent/EP0655440A3/de not_active Withdrawn
- 1994-10-14 ZA ZA948094A patent/ZA948094B/xx unknown
- 1994-10-14 AU AU75837/94A patent/AU685841B2/en not_active Ceased
- 1994-10-17 NZ NZ264713A patent/NZ264713A/en unknown
- 1994-10-17 IL IL11131494A patent/IL111314A/xx not_active IP Right Cessation
- 1994-10-17 HU HU9402983A patent/HU218669B/hu not_active IP Right Cessation
- 1994-10-19 CO CO94047587A patent/CO4290356A1/es unknown
- 1994-10-20 RU RU94037964A patent/RU2136662C1/ru active
- 1994-10-20 CN CN94117149A patent/CN1061341C/zh not_active Expired - Fee Related
- 1994-10-21 FI FI944969A patent/FI944969A/fi unknown
- 1994-10-21 BR BR9404203A patent/BR9404203A/pt not_active Application Discontinuation
- 1994-10-21 CZ CZ942604A patent/CZ260494A3/cs unknown
- 1994-10-21 NO NO943999A patent/NO301369B1/no not_active IP Right Cessation
- 1994-10-21 PL PL94305543A patent/PL179561B1/pl unknown
- 1994-10-22 KR KR1019940027045A patent/KR950011406A/ko not_active Application Discontinuation
- 1994-10-24 JP JP6257775A patent/JP2638752B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| TW270114B (it) | 1996-02-11 |
| PL179561B1 (pl) | 2000-09-29 |
| BR9404203A (pt) | 1995-07-04 |
| CN1061341C (zh) | 2001-01-31 |
| EP0655440A2 (de) | 1995-05-31 |
| EP0655440A3 (de) | 1996-11-06 |
| HUT70848A (en) | 1995-11-28 |
| FI944969A (fi) | 1995-04-23 |
| IL111314A (en) | 1999-08-17 |
| CO4290356A1 (es) | 1996-04-17 |
| CZ260494A3 (en) | 1995-10-18 |
| JPH07149723A (ja) | 1995-06-13 |
| NO943999D0 (no) | 1994-10-21 |
| ZA948094B (en) | 1995-04-24 |
| AU685841B2 (en) | 1998-01-29 |
| CN1105988A (zh) | 1995-08-02 |
| PL305543A1 (en) | 1995-05-02 |
| NZ264713A (en) | 1996-05-28 |
| IL111314A0 (en) | 1994-12-29 |
| HU218669B (hu) | 2000-10-28 |
| KR950011406A (ko) | 1995-05-15 |
| US5494928A (en) | 1996-02-27 |
| AU7583794A (en) | 1995-05-11 |
| RU2136662C1 (ru) | 1999-09-10 |
| FI944969A0 (fi) | 1994-10-21 |
| NO943999L (no) | 1995-04-24 |
| RU94037964A (ru) | 1996-09-10 |
| HU9402983D0 (en) | 1995-02-28 |
| CA2132883A1 (en) | 1995-04-23 |
| JP2638752B2 (ja) | 1997-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO301369B1 (no) | 1-aminoetylindolderivater | |
| US5571833A (en) | Tryptamine analogues, their synthesis and their use as 5-HT1 -like or 5-HT2 receptor agonists | |
| CA2015996C (en) | Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals | |
| JP5070042B2 (ja) | 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物 | |
| CN102091068B (zh) | 作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物 | |
| CN1980934B (zh) | 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物 | |
| SE452459B (sv) | Indol-5-metansulfonamid, en farmaceutisk komposition och ett forfarande for framstellning av foreningen | |
| KR20040010709A (ko) | 5-ｈｔ6 수용체 친화력을 갖는 4-피페라지닐인돌 유도체 | |
| US20060074084A1 (en) | Inhibitors of soluble adenylate cyclase | |
| PL182480B1 (pl) | Nowe tricykliczne pochodne pirazolu, sposób ich wytwarzania oraz zawierające je środki lecznicze | |
| WO1993012786A1 (en) | Indolinone derivatives | |
| CA2147451C (en) | 3-indolylpiperidines | |
| NO851862L (no) | Fremgangsmaate ved fremstilling av nye pyrrolobenzimidazoler | |
| EA011714B1 (ru) | Производные n-(1h-индолил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии | |
| AU2006268713A1 (en) | Benzimidazole derivatives as 5-HT6,5-HT24 | |
| US20080004268A1 (en) | Inhibitors of soluble adenylate cyclase | |
| EP2261206A1 (en) | Indolinone compound | |
| Nagarathnam | A facile synthesis of 3‐substituted indoles | |
| CZ51699A3 (cs) | Způsob přípravy N-/1-n-butyl-4-piperidyl)methil/ -3,4-dihydro-2H/1,3/ oxazino /3,2-a/ indol-10-karboxamidu a jeho solí a meziprodukty pro tento způsob | |
| NO164899B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolylindolforbindelser. | |
| NO300375B1 (no) | 6-okso-azepinoindolforbindelser, mellomprodukter for fremstilling av disse, og legemidler inneholdende disse forbindelser | |
| US3976645A (en) | Process for the preparation of 10-(halophenyl)-2,3,4,10-tetrahydropyrimido-[1,2-a]indol-10-ol | |
| SG177286A1 (en) | Intermediates and processes for the preparation of 4- (acetylamino) ) -3- [ (4-chloro-phenyl) thio] -2-methyl-1h-indole-1-acetic acid | |
| JPS6045577A (ja) | ２−アザビシクロ〔２．２．２〕オクタン誘導体 | |
| WO1995021844A1 (en) | 5ht2b receptor antagonists condensed indoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN APRIL 2002 |